Home/Pipeline/HS-10352

HS-10352

KRAS G12C-mutated Solid Tumors

Phase I/IIActiveNCT05613261

Key Facts

Indication
KRAS G12C-mutated Solid Tumors
Phase
Phase I/II
Status
Active
Company

About Hansoh Pharma

Hansoh Pharma's mission is to develop and deliver innovative, high-quality medicines that address significant unmet medical needs in China and worldwide. The company has achieved a dominant position as one of China's most valuable pharmaceutical entities, built upon the commercial success of flagship products and a rich pipeline of novel candidates. Its strategy leverages a fully integrated platform from discovery to commercialization, with a sharp focus on oncology and CNS disorders, while actively pursuing strategic global partnerships to expand its international footprint. Hansoh's substantial R&D investment and manufacturing scale underpin its ambition to become a global biopharmaceutical leader.

View full company profile